Cidara Therapeutics

Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-infectives for the treatment of diseases. The company is developing a pipeline of product and development candidates, with an initial focus on fungal infections. The company's primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of invasive fungal infections. In addition, the company's proprietary Cloudbreak? platform is designed to discover compounds that directly kill pathogens and also direct a patient's immune system to attack and eliminate pathogens.
  • TickerCDTX
  • ISINUS1717571079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ValuEngine Rating and Forecast Report for CDTX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch